In Vitro Diagnostics - United Kingdom

  • United Kingdom
  • The projected revenue in the In Vitro Diagnostics market market in the United Kingdom is set to reach US$1.97bn in 2024.
  • This market is expected to exhibit a compound annual growth rate (CAGR 2024-2028) of 3.61%, leading to a market volume of US$2.27bn by 2028.
  • When compared globally, the United States will generate the highest revenue, amounting to US$33,780.00m in 2024.
  • The United Kingdom has seen a significant increase in demand for advanced In Vitro Diagnostics technologies in its medical technology market.

Key regions: Europe, Italy, Spain, Germany, China

 
Market
 
Region
 
Region comparison
 
Currency
 

Analyst Opinion

The In Vitro Diagnostics market in United Kingdom has been experiencing steady growth in recent years.

Customer preferences:
Customers in the United Kingdom have shown a growing demand for In Vitro Diagnostics products and services. This can be attributed to several factors. Firstly, there is an increasing awareness among the general population about the importance of early detection and prevention of diseases. As a result, more people are opting for regular diagnostic tests to monitor their health. Additionally, advancements in technology have made In Vitro Diagnostics more accessible and convenient, allowing customers to perform certain tests at home or in a point-of-care setting. This has further fueled the demand for these products and services.

Trends in the market:
One of the key trends in the In Vitro Diagnostics market in the United Kingdom is the shift towards personalized medicine. With the advancements in genetic testing and molecular diagnostics, healthcare providers are now able to tailor treatments to individual patients based on their genetic makeup. This trend is driving the demand for genetic testing kits and companion diagnostics, which are used to identify specific biomarkers and guide treatment decisions. Another trend in the market is the increasing adoption of point-of-care testing. This allows for faster and more convenient diagnosis, particularly in remote or underserved areas. The demand for point-of-care testing devices is expected to continue to grow as healthcare providers seek to improve patient outcomes and reduce healthcare costs.

Local special circumstances:
The United Kingdom has a well-established healthcare system, which provides universal access to healthcare services. This has created a favorable environment for the growth of the In Vitro Diagnostics market. Additionally, the country has a strong research and development sector, which has led to the development of innovative diagnostic technologies. The presence of leading healthcare companies and academic institutions has also contributed to the growth of the market.

Underlying macroeconomic factors:
The In Vitro Diagnostics market in the United Kingdom is influenced by several macroeconomic factors. Firstly, the aging population in the country is driving the demand for diagnostic tests, as older individuals are more likely to develop chronic diseases that require regular monitoring. Secondly, the increasing healthcare expenditure in the country is supporting the growth of the market. The government has been investing in healthcare infrastructure and promoting the adoption of innovative diagnostic technologies. Lastly, the United Kingdom's strong economy and high disposable income levels have allowed individuals to afford diagnostic tests and services. In conclusion, the In Vitro Diagnostics market in the United Kingdom is experiencing growth due to increasing customer preferences for early detection and prevention of diseases, as well as advancements in technology. The market is characterized by trends such as personalized medicine and the adoption of point-of-care testing. The favorable healthcare system, strong research and development sector, and underlying macroeconomic factors contribute to the growth of the market.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on medical devices and IVD revenues allocated to the country where the money is spent at manufacturer price levels excluding VAT.

Modeling approach / Market size:

Modeling employs a top-down approach with a bottom-up validation, using financial information of the key players by market. Market sizes are determined by a top-down approach, based on a specific rationale for each market market and allocated to the covered countries according to the global market shares. As a basis for evaluating markets, we use relevant key market indicators and data from country-specific associations, such as healthcare expenditure per capita, health risk factors, healthcare system, and regulations concerning medical products. Next, we use further relevant key market indicators and data from country-specific associations, such as healthcare expenditure per capita, health risk factors, healthcare payer system, and regulations concerning medical products. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level.

Overview

  • Revenue
  • Key Players
  • Analyst Opinion
  • Global Comparison
  • Methodology
  • Key Market Indicators
Please wait

Contact

Get in touch with us. We are happy to help.
Statista Locations
Contact Meredith Alda
Meredith Alda
Sales Manager– Contact (United States)

Mon - Fri, 9am - 6pm (EST)

Contact Yolanda Mega
Yolanda Mega
Operations Manager– Contact (Asia)

Mon - Fri, 9am - 5pm (SGT)

Contact Kisara Mizuno
Kisara Mizuno
Senior Business Development Manager– Contact (Asia)

Mon - Fri, 10:00am - 6:00pm (JST)

Contact Lodovica Biagi
Lodovica Biagi
Director of Operations– Contact (Europe)

Mon - Fri, 9:30am - 5pm (GMT)

Contact Carolina Dulin
Carolina Dulin
Group Director - LATAM– Contact (Latin America)

Mon - Fri, 9am - 6pm (EST)